About
Whether you are a larger company conducting the diligence or a target being examined, you need to attend this annual event to ensure the value of the IP with a thorough and effective IP due diligence review.
IP due diligence is now a central concern and struggle for companies in life science-related industries, due to the substantial growth of mergers and acquisitions, spin-outs, and divestitures, as well as the evolving role of licensing and collaborative arrangements. If the due diligence is not properly conducted, you run the risk of loss of reputation, loss of profits, or even ruin.
Furthermore, since the intellectual property at issue can make or break a deal, it is imperative that you are aware of all of the current changes to patent practices. Proposed legislation, recent case law and proposed USPTO Rules complicate the patent landscape even further.
This is the ONLY proven event where an experienced faculty of leading IP practitioners and in-house patent and IP counsel will not only give you the most up-to-date information about a constantly evolving patent landscape, but will show you how to incorporate these changes into your diligence review to accurately analyze the value of the IP. You will also learn best practices from representatives of leading companies who have “been there” and managed successful and cost-effective IP diligence review, including practical advice and the tools you need to develop flexible checklists, structure the review based on the type of deal, evaluate the patent portfolio, prepare for the review and much more.
About
Whether you are a larger company conducting the diligence or a target being examined, you need to attend this annual event to ensure the value of the IP with a thorough and effective IP due diligence review.
IP due diligence is now a central concern and struggle for companies in life science-related industries, due to the substantial growth of mergers and acquisitions, spin-outs, and divestitures, as well as the evolving role of licensing and collaborative arrangements. If the due diligence is not properly conducted, you run the risk of loss of reputation, loss of profits, or even ruin.
Furthermore, since the intellectual property at issue can make or break a deal, it is imperative that you are aware of all of the current changes to patent practices. Proposed legislation, recent case law and proposed USPTO Rules complicate the patent landscape even further.
This is the ONLY proven event where an experienced faculty of leading IP practitioners and in-house patent and IP counsel will not only give you the most up-to-date information about a constantly evolving patent landscape, but will show you how to incorporate these changes into your diligence review to accurately analyze the value of the IP. You will also learn best practices from representatives of leading companies who have “been there” and managed successful and cost-effective IP diligence review, including practical advice and the tools you need to develop flexible checklists, structure the review based on the type of deal, evaluate the patent portfolio, prepare for the review and much more.
Contents & Contributors
Defining the Company’s Goals before You Begin the Due Diligence Review and Crafting an Accordant Checklist
Thomas M. Argentieri, Ph.D., Senior Director, Licensing, Global Business Development, Wyeth Pharmaceuticals (Collegeville, PA)
Theresa A. Devlin, Senior Patent Attorney, AstraZeneca Pharmaceuticals LP(Boston, MA)
Mark S. Cohen, Senior Partner and Chair of Life Science Group, Pearl Cohen Zedek Latzer LLP (New York, NY)
Henry P. Doggrell, Vice President and General Counsel, GTx, Inc. (Memphis, TN)
Christine McCormack, Senior Patent Attorney, AstraZeneca Pharmaceuticals LP (Boston, MA)
Navigating the Dynamic Labryinth of Recent Cases, Rules, and Regulations Affecting the Company's Due Diligence Analysis
Mary Ann Dillahunty, Vice President, Intellectual Property, Oncolytics Biotech, Inc. (Calgary, AB)
Eric J. Marandett, Partner and Chair, Intellectual Property Litigation Group Choate Hall & Stewart LLP (Boston, MA)
Setting up an Electronic Data Room to Protect the Company's Vital Interests
Richard J. Berman, Partner, Arent Fox LLP (Washington, DC)
Steven A. Bossone, Patent Counsel, Shire HGT, Inc. (Cambridge, MA)
Thomas David, Senior Vice President, Operations, Avalon Pharmaceuticals, Inc. (Germantown, MD)
Sweet Land of Libert...Let Freedom to Operate Ring!
Michelle L. Lewis, Senior Patent Attorney, ZymoGenetics, Inc. (Seattle, WA)
David S. Resnick, Partner and Leader, Biotechnology/Chemistry Team
Nixon Peabody LLP (Boston, MA)
Brian J. Walsh, Assistant General Counsel, ZymoGenetics, Inc. (Seattle, WA)
Uncovering the Vulnerable Spots for "In Licensing" Deals
Matthew J. Golden, Legal Director, Patents, Schering-Plough Corporation (Kenilworth, NJ)
Renee Kosslak, Ph.D., General Patent Counsel, PDL BioPharma, Inc. (Redwood City, CA)
I've Got A Trade Secret: Incorporating the Target Company's Soft IP Assets in Your Due Diligence Analysis
Carl C. Butzer, Partner, Jackson Walker LLP (Dallas, TX)
Andrew A. Paul, Senior Counsel, Procter & Gamble Company (Cincinnati, OH)
Using Due Diligence to Reveal, Analyze, and Measure the Specific Risks for the Pharmaceutical or Biotech Target or Licensor
Kate Deeley, Senior Vice President & General Counsel, Trubion Pharmaceuticals (Seattle, WA)
Seth H. Jacobs, Senior Patent Counsel, Pfizer, Inc. (New York, NY)
George C. Jen, Ph.D., Senior Director, Legal Global Partnership Roche Palo Alto LLC (Palo Alto, CA)
Dissecting the Due Diligence Challenges for a Pharma/Biotech Acquirer, Licensee, or Collaborator
Allen R. Baum, Partner, Brinks Hofer Gilson & Lione P.C. (Raleigh, NC)
Bruce A. Pokras, Senior Corporate Counsel, Pfizer, Inc. (New York, NY)
Balancing between the Company's Attorney-Client Privilege and the Need to Disclose Information
Thomas E. Duley, Of Counsel, Morgan Lewis & Bockius LLP (San Francisco, CA)
Adjusting Your Due Diligence Approach in Transactions with Universities
Wesley D. Blakeslee, Executive Director of Johns Hopkins Technology Transfer Johns Hopkins University (Baltimore, MD)
Tena Herlihy, Counsel, MIT Technology Licensing Office (Cambridge, MA)
Jeffrey M. Sears, Ph.D., Associate General Counsel, Columbia University (New York, NY)
Analyzing the Needs of a Venture Capitalist in the Company's Due Diligence Research
Mary Lincoln Campbell, Managing Director, EDF Ventures (Ann Arbor, MI)
Thomas D. Weldon, Chairman and Managing Director, Accuitive Medical Ventures (Duluth, GA)
Alex Zisson, Partner, Thomas, McNerney & Partners, LLC (Stamford, CT)
Assessing the Findings of the Due Diligence Review upon Its Completion
James M. Gould, Legal Director -Global Patent Litigation, Schering-Plough Corporation (Kenilworth, NJ)
Mark D. Sweet, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP (Washington, D.C.)
Publication Details